SRPTSarepta Therapeutics, Inc.

Nasdaq sarepta.com


$ 143.48 $ 1.24 (0.87 %)    

Thursday, 01-Aug-2024 12:30:58 EDT
QQQ $ 462.43 $ -11.45 (-2.42 %)
DIA $ 403.70 $ -6.35 (-1.55 %)
SPY $ 544.53 $ -8.04 (-1.46 %)
TLT $ 95.71 $ 0.65 (0.69 %)
GLD $ 226.15 $ -0.67 (-0.3 %)
$ 142.24
$ 143.89
$ 143.40 x 200
-- x --
$ 140.82 - $ 144.57
$ 55.25 - $ 173.25
1,040,382
na
14.1B
$ 0.79
$ 834.35
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 10-31-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 03-01-2018 12-31-2017 10-K
27 11-01-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-25-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-26-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-upgrades-sarepta-therapeutics-to-outperform-announces-182-price-target

RBC Capital analyst Brian Abrahams upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Sector Perform to Outperform and announc...

 jim-cramer-says-dont-sell-match-group-youve-just-got-a-very-very-smart-investor-in-there

Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run c...

 piper-sandler-maintains-overweight-on-sarepta-therapeutics-maintains-205-price-target

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and maintains $205 price tar...

 needham-reiterates-buy-on-sarepta-therapeutics-maintains-235-price-target

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $235 price target.

 citigroup-downgrades-sarepta-therapeutics-to-neutral-raises-price-target-to-176

Citigroup analyst David Hoang downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Buy to Neutral and raises the price target ...

 morgan-stanley-maintains-overweight-on-sarepta-therapeutics-raises-price-target-to-200

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price ...

 evercore-isi-group-maintains-in-line-on-sarepta-therapeutics-raises-price-target-to-185

Evercore ISI Group analyst Gavin Clark-Gartner maintains Sarepta Therapeutics (NASDAQ:SRPT) with a In-Line and raises the pr...

 bmo-capital-maintains-outperform-on-sarepta-therapeutics-raises-price-target-to-200

BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price tar...

 leerink-partners-maintains-outperform-on-sarepta-therapeutics-raises-price-target-to-230

Leerink Partners analyst Mani Foroohar maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price t...

 draftkings-and-dell-were-among-the-10-biggest-large-cap-stock-gainers-last-week-june-16-june-22-are-these-in-your-portfolio

Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKN...

 growth-stocks-leave-value-stocks-in-the-dust-4-reasons-for-biggest-monthly-lead-in-over-a-year

Technology sector dominates growth stocks, boosted by strong earnings and investor confidence. Value stocks struggle due to les...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION